The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InRoquefort Therapeutics PLC (LSE:ROQ) has announced a transformative deal to acquire an exclusive worldwide license for the cancer drug AO-252. The transaction, valued at £32 million, is structured as a Reverse Takeover (RTO) and marks a significant shift in the company's strategic direction. To support this transition, the firm plans to raise £8.5 million in fresh capital to fund its evolution into a clinical-stage oncology business. The drug AO-252 is a small molecule targeting the TACC3 protein, which is frequently found in aggressive tumors. This move represents a substantial expansion for Roquefort, which was previously valued at less than £1.5 million. Investors are viewing the deal as a major milestone that provides both a high-potential clinical asset and the necessary capital for development.